As the founder and President of MAPS, Rick Doblin will present an exploration into the future of psychedelics, focusing on both drug policy reform and sponsoring cutting-edge psychedelic research. He will discuss the necessity of evidence-based drug policy reform and bipartisanship, as well as the potential for policy frameworks that prioritize public health, safety, and harm reduction. Lastly, Rick will share groundbreaking insights into the therapeutic investigations of psychedelic-assisted therapy for various mental health conditions, including post-traumatic stress disorder (PTSD).